 |
|
|
|
 |
|
|
| Article 1 to 10 out of 10 concerning Dako Denmark A/S
|
-
Dako's new Board and Management in place
(08/31/2007)
Dako's new board is now in place and a new Corporate Vice President, Operations, has been appointed as member of the Corporate Management. Two new board members entered Dako's Board of Directors as of 28 August:- Staffan Ek, former Head of Roches' ...
-
Dako enters new collaboration on targeted therapies for non-small cell lung cancer
(08/22/2007)
Dako has entered into collaboration with Genentech, OSI and Roche for the clinical development and application for a Premarket Approval Supplement (sPMA) and CE marking of EGFR pharmDx for use of the EGFR pharmDx test as a potential aid in the ...
-
Oxoid acquires Dako's Microbiology business
(09/21/2006)
Oxoid, a business unit within the Fisher Biosciences group, has acquired Dako's Microbiology business. The purchase expands Oxoid's range of clinical microbiology products for the detection of viral gastroenteritis, sexually transmitted diseases, ...
-
DakoCytomation A/S becomes Dako A/S
(11/03/2005)
On November 1, 2005 DakoCytomation A/S changed its name to Dako. The name change was approved by the shareholders on September 23, 2005."We are moving forward with a stronger, simpler version of our name and logo. Since the merger in 2002, we have ...
-
Patrik Dahlén new CEO of DakoCytomation A/S
(09/27/2005)
The Board of Directors of DakoCytomation A/S has resolved to appoint Patrik Dahlén CEO of DakoCytomation. Patrik Dahlén has been acting CEO since August 1, 2005."During the past few months we have searched the global market for potential candidates ...
-
DakoCytomation announces potential sale of its microbiology activities
(09/13/2005)
DakoCytomation, a world leader in cancer diagnostics, has decided to investigate the possibilities of selling its microbiology activities in order to sharpen its focus on cell-based cancer diagnostics."We see this as a strategic move to create a ...
-
New CEO of DakoCytomation A/S
(08/02/2005)
After six years of fruitful service Jes Østergaard is passing the mantle to Patrik Dahlén, board member at DakoCytomation since 2003 and CEO of the company BioImage A/S. Jes Østergaard will continue as a consultant for the management of ...
-
DakoCytomation and ViroNovative enter licensing agreement on Human Metapneumovirus
(05/09/2005)
DakoCytomation A/S and ViroNovative BV have entered into a licensing agreement for the development and sales of diagnostic products for the detection of Human Metapneumovirus.Human metapneumovirus was discovered by a team of scientists led by Prof. ...
-
DakoCytomation and Epitomics announce license and development agreement concerning rabbit monoclonal antibodies
(10/19/2004)
DakoCytomation A/S, the leading global provider of in vitro diagnostic systems for Anatomic Pathologists, announced it entered into a license and a development agreement with Epitomics, Inc, the founder of rabbit monoclonal antibody technology. ...
-
DakoCytomation Offers New Diagnostic Option for Breast Cancer Patients in Europe
(06/01/2004)
Copenhagen, Denmark. DakoCytomation now offers the HER2 FISH pharmDx(TM) test for use as an aid in identifying European breast cancer patients eligible for Herceptin(TM) therapy. Herceptin(TM), marketed by Roche in Europe, is a targeted monoclonal ...
Additional information
Dako Denmark A/S
Glostrup, Denmark
Company
|
|
|
|
|
|
Top
